Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals
admin 26th July 2017 Uncategorised 0Eli Lilly’s rheumatoid arthritis med baricitinib was pegged as one of 2017’s hottest launches—and a threat to Pfizer’s rival drug Xeljanz. Well, cast aside those expectations. The Lilly drug won’t roll this year, and Xeljanz looks like the near-term winner, even as competition in RA heats up.
More: Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals
Source: fierce